GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » 5-Year Yield-on-Cost %
Switch to:

Biogen (MEX:BIIB) 5-Year Yield-on-Cost %

: 0.00 (As of Today)
View and export this data going back to 2013. Start your Free Trial

Biogen's yield on cost for the quarter that ended in Mar. 2023 was 0.00.


The historical rank and industry rank for Biogen's 5-Year Yield-on-Cost % or its related term are showing as below:



MEX:BIIB's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.07
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen 5-Year Yield-on-Cost % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Biogen's 5-Year Yield-on-Cost % falls in comparison to its industry or sector. The grey bar indicates the 5-Year Yield-on-Cost %'s extreme value range as defined by GuruFocus.



Biogen 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Biogen is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Biogen  (MEX:BIIB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Biogen 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Biogen's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines